A retrospective multicenter analysis of 364 patients concluded that additional MEK inhibition to immune checkpoint inhibition has potential to increase survival of NRAS-mutated melanoma patients and improve clinical benefit (Kirchberger et al., 2018). This evidence concerns the gene MAP2K7 and melanoma.